No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Polatuzumab vedotin plus obinutuzumab and lenalidomide shows high complete response rates in patients with relapsed or refractory follicular lymphoma

Phase 1b/2 study (multi-centre, single-arm)

byKathleen Lau

December 2, 2021

in StudyGraphics

Reading Time: 1 min read

High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia

RelatedReports

Lessons from real-world implementation of lung cancer screening

AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025

Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025

New genetic link in pulmonary arterial hypertension holds therapeutic promise

Chronic Disease

Hereditary erythrocytosis is associated with a fetal-like EPO isoform

June 2, 2025

AI Roundup

Physical disability and psychological distress demonstrate marked progression after diagnosis of cancer

May 28, 2025

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma

Surgical site anesthetic infusion may enhance analgesia after mastectomy

Peripherally inserted central catheters are associated with twice as many complications than midline catheters when used short-term

AAP recommends focus on nutrient-rich foods in schools

Smartphone-based intervention reduced body mass index and obesity in school children

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports